ClinicalTrials.gg
CompletedNCT00171158Updated Jun 25, 2021Results posted

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

A Phase 2 interventional study of imatinib mesylate in Philadelphia Chromosome Positive CML, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.

Primary conditionBlast CrisisRegistry: Leukemia, Myelogenous, Chronic, BCR-ABL PositiveReclassifiedWhy we changed it
Registry
Leukemia, Myelogenous, Chronic, BCR-ABL Positive — the first condition term the registry derived for this study.
ClinicalTrials.gg
Blast Crisis
Why
  1. The study's title name Blast Crisis, a narrower term within Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 1 month after the study started (first participant enrolled Jul 1999, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing imatinib in Blast Crisis — 1 open to participants now, 1 under way, none of them phase 3. imatinib · Blast Crisis.

Enrollment
2nd of 10
260 · median 48
Started
1999
the only one that year
Phase 2
7 of 15
none open now
Registered
7th of 15
by date
Lead sponsor
2 of 15
Novartis Pharmaceuticals

Among the 15 studies testing imatinib in Blast Crisis, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 1999, is one of 7 in phase 2, and was the 7th registered.

Blast Crisis

361 studies on the registry are indexed under Blast Crisis; 16 are open to participants now.

Browse Blast Crisis studies →

Open to participants now

1 of the 15 studies testing imatinib in Blast Crisis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Blast Crisis studies recruiting now, 9 (64%) set no upper age limit and 2 (14%) stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing imatinib in Blast Crisis, or all of them as a file.
02

Study summary

This extension II study allowed for further follow-up of the disease under treatment with imatinib mesylate and allow the participants to continue to receive imatinib mesylate.

03

Conditions studied

  • Philadelphia Chromosome Positive CML

Keywords

  • Chronic Myelogenous Leukemia
  • CML
  • Philadelphia Chromosome
  • Blast crisis
  • Imatinib mesylate
04

In context

Blast Crisis Reclassified

361 studies on the registry are indexed under Blast Crisis; 16 are open to participants now.

This study's enrollment of 260 is above the median of 36 across 264 interventional studies indexed under Blast Crisis.

Browse Blast Crisis studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Blast Crisis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with Philadelphia chromosome positive chronic myelogenous leukemia (CML) in myeloid blast crisis (including both newly diagnosed and the participants who received prior therapy for accelerated or blastic phases), defined as either:
  1. ≥ 30% blast in peripheral blood and /or bone marrow
  2. by flow cytometry criteria
  1. To be categorized as "newly diagnosed", participants with CML in blast crisis were not to have received specific therapy for CML accelerated or blast phases, with the exception of interferon-alpha or hydroxyurea.
  1. serum glutamic-oxaloacetic transaminase () and serum glutamic-pyruvic transaminase (SGPT) not more than 3 times the (ULN) (or not more than 5 times the ULN if clinically suspected leukemic involvement of the liver), serum creatinine concentration not more than 2 times the ULN, and total serum level not more than 3 times the ULN at the laboratory where the analyses were performed.
  1. A negative pregnancy test in participants of .

Exclusion criteria

Exclusion Criteria:

  1. Participants with an (ECOG) performance status score ≥ 3.
  2. Participants previously treated for blast crisis were not to have received any of the following with respect to Day 1 of the study: busulfan within six weeks, interferon-alpha within 48-hours, hydroxyurea within 24-hours, homoharringtonine within 14 days, low-dose, moderate dose or high dose cytosine arabinoside within 7, 14 and 28 days respectively, anthracyclines, mitoxantrone, or etoposide within 21 days.
  3. Participants receiving any hematopoietic stem cell transplantation within six weeks of Day 1.
  4. Participants receiving any other agents within 28 days of Day 1.
  5. Participants with Grade 3/4 cardiac disease or any other serious concurrent medical conditions.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Imatinib Mesylate (STI571)

    Participants initially received STI571 capsules or tablets, orally, initially once daily (400 mg) or (600 mg). The dosage was escalated from 400 mg to 600 mg and from 600 mg to 800 mg, on an individual basis as per the investigator's judgement. Treatment continued until death, or the development of intolerable toxicity, or the participant was considered not to benefit from treatment, whichever came first.

    Drug: imatinib mesylate

Interventions

07

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the number of events of death, expressed as a percentage, from the start of treatment to death, due to any reason.

    Time frame: From first dose until death of the patient, up to 14 years.

  2. Overall Survival (by Month)

    Overall survival was defined as the time between start of treatment and death due to any reason. Overall survival for the participants was calculated by Kaplan-Meier estimates per month. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up.

    Time frame: From first dose until death of the patient, up to 14 years.

08

Results

Posted Jun 25, 2021

Participant flow

The overall study was conducted at 28 investigative sites in 6 countries from 26 July 1999 to 22 April 2013. A total of 260 participants were enrolled in the core Study CSTI57A0102, of which 21 participants completed the treatment and were enrolled in the extension Study CSTI571A0102E1. 13 participants discontinued from the extension Study CSTI571A0102E1, and 8 of them were enrolled in the extension Study CSTI571A0102E2.

Core Study
Participant flow — Core Study
MilestoneImatinib Mesylate (STI571)
Started260
Completed21
Not completed239
Withdrew: Death27
Withdrew: Unsatisfactory therapeutic effect163
Withdrew: Protocol violation4
Withdrew: Administrative problems1
Withdrew: Adverse event, non-fatal21
Withdrew: Consent withdrawn by subject6
Withdrew: No longer required drug (bmt)14
Withdrew: Abnormal laboratory values2
Withdrew: Lost to follow-up1
E2 Extension
Participant flow — E2 Extension
MilestoneImatinib Mesylate (STI571)
Started8
Completed1
Not completed7
Withdrew: Other7

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the number of events of death, expressed as a percentage, from the start of treatment to death, due to any reason.

Time frame:
From first dose until death of the patient, up to 14 years.
Reported as:
Number · percentage of participants
Overall Survival
percentage of participantsImatinib Mesylate (STI571)
Overall Survival89.2
PrimaryOverall Survival (by Month)

Overall survival was defined as the time between start of treatment and death due to any reason. Overall survival for the participants was calculated by Kaplan-Meier estimates per month. The time was censored at the date of last contact for participants who discontinued treatment and were in survival follow-up.

Time frame:
From first dose until death of the patient, up to 14 years.
Reported as:
Number · percentage of participants
Overall Survival (by Month)
percentage of participantsImatinib Mesylate (STI571)
12 Months32.7 (27.0 to 38.5)
24 Months18.7 (14.2 to 23.8)
36 Months15.4 (11.2 to 20.2)
48 Months14.5 (10.4 to 19.2)
60 Months9.1 (5.7 to 13.4)
72 Months8.4 (5.2 to 12.7)
84 Months7.5 (4.3 to 11.8)
96 Months7.5 (4.3 to 11.8)
108 Months7.5 (4.3 to 11.8)
120 Months6.6 (3.5 to 11.0)
132 Months5.5 (2.6 to 10.0)
144 Months5.5 (2.6 to 10.0)
156 Months5.5 (2.6 to 10.0)

Adverse events

Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV) up to 14 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib Mesylate (STI571)—0/260 (0%)0/260 (0%)

Baseline characteristics

The Intent-to-treat (ITT) population included all participants who enrolled in the study.

Age, Continuous
Age, Continuous(years)Imatinib Mesylate (STI571)
Median56 (19 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib Mesylate (STI571)
Female124
Male136
09

Study locations

10 sites
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Dana Faber Institute
    Boston, Massachusetts 02115, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Poitiers, France
  • Novartis Investigative Site
    Frankfurt/Main, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Mannheim, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Monza, Italy
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 1999 to primary completion in Apr 2013, 165 months.

Results were first posted in Jun 2021, 8 years 2 months after primary completion.

Of 25 phase 2 interventional studies under Blast Crisis, half reached primary completion within 119 months of starting (the median), counting those still running; a quarter within 64 and three quarters within 165. This study's 165 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
StartActual
Jul 26, 1999
Primary completionActual
Apr 2013
CompletionActual
Apr 22, 2013
Results first posted
Jun 25, 2021
Last update
Jun 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00171158
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Jul 26, 1999
Primary completion
Apr 2013
Completion
Apr 22, 2013
Results posted
Jun 25, 2021
Last update
Jun 25, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion